Background This study aims to estimate the burden of cancer in England and Wales using disability-adjusted life years (DALYs) and to determine if the ranking of relative importance changes with metric used.
Background
Commonly, readily available event-based metrics such as mortality and registrations data are used for resource allocation. However, single measures provide a limited view of the disease burden. The burden of a disease is the impact of the health loss due to the disease in terms of mortality, morbidity or financial means. 1 In order to assess the overall health of the population by combining impacts of morbidity and mortality, summary measures of population health such as disability-adjusted life years (DALYs) have been developed. DALYs provide a health gap measure of potential years of life lost due to premature death and equivalent years of healthy life lost by virtue of individuals being in states of poor health or disability. 2 DALY is a time-based measure that combines years of potential life lost (YLL) and years lived with disability (YLD): DALY ¼ YLL þ YLD.
One DALY is equivalent to 1 year of healthy life lost. The key issues surrounding summary measures are the technical issues of calculations, definition and measurement of health states, valuation of health states and inclusion of other social values.
Disease (GBD) programme for the Europe-A region 5 or from the World Bank study 6 were imputed. Mortality-based measures have conventionally been used to set priorities and inform policy decisions. A question of importance for priority setting and policy decision is the extent to which the ranking of diseases changes with the metric used. This study aims to estimate the average burden of disease from cancer in England and Wales using DALYs during [2002] [2003] [2004] [2005] [2006] to examine whether cancer ranking varies by the metric used. This paper quantifies both YLL and YLD without direct borrowing from European regional estimates.
Methods
We used the published methods of the GBD study to calculate DALYs. 1 Data needed to estimate DALYs included mortality, incidence, duration, disability and age at diagnosis. In addition, disability weights (DWs), discount rate (3%) and age weighting were applied. Different data sources were used for each of the estimated parameters:
(i) Population: Office for National Statistics, England and Wales, years 2002 -2006. 7 -11 (ii) Mortality: Office for National Statistics, coded as per the International Classification of Diseases (ICD-10). Deaths attributed to 'ill-defined' malignancies were included in the 'other' cancers category. 7 -11 (iii) Reference life Years of life lost due to cancer among all persons that die of cancer are the sum of years that they would have lived if they had completed the reference life expectancy attributed to their age at the time of their death. The simplified version of the complete equation applied was:
where L was the life expectancy obtained from reference life tables and 0.03, the discount rate. 25 The mid-point of the age group was considered the average age at death for the age group. YLD estimates the consequences of living in less than perfect health based on the length of time with condition and the accompanying level of disability. YLD is dependent on the number of new cases, disease duration and assigned DW. This means YLD considers health losses that accrue from cancer onsets during the selected study years. Disease duration refers to the average time spent with disease 1 . DWs are pre-assigned preference values for different health states as measures of the impact of the condition based on the preferences of panels of health experts. 25 The simplified version of the complete equation without age weighting used to estimate YLD was:
where I is the incidence, DW is the disability weight and d is the average duration of disability. 25 The study design to calculate DALYs was based on the GBD study, 25 which included a simplification of disease histories by subdividing it into different stages. Duration and DWs were assigned for each stage. For some tumours, the model subdivided groups by clinical stage or size of tumour at diagnosis and/or histological type.
Cases of cancer were assumed to follow one of two possible prognosis paths: those who were destined to survive their cancer and those who were destined to die from it. A DW on a scale from 0 ( perfect health) to 1 (death) was applied to each cancer stage. Duration of each disease stage was estimated taking into account cancer survival in England and Wales and natural history of each cancer derived from the Netherlands study 26 and Victorian BoD study. 24 Five-year survival rates were used to estimate cure rates and YLD was estimated for survivors and nonsurvivors separately for all site-specific cancers. The duration of each disease stage was based on the Victorian BoD study from which total duration data was used to fit survival proportions in England and Wales. Supplementary data, Appendix 1 presents the stage-specific DWs as derived from Victorian BoD. 24 If the disease model for a particular cancer included several stages with different DWs, overall YLD were calculated as the product of the time spent in each specified health state and of health state-specific DW. Figure 1 represents a schematic diagram of the natural history of cancer. Initial diagnosis and treatment were assumed to be completed within 6 months. For long-term survivors, a DW of 0 was applied after 5 years. For non-survivors, after initial diagnosis, remaining stages include 'irradically removed' stage, pre-terminal and terminal stages. 24 YLD estimations required several assumptions. Cancer registrations were considered operationally as disease incidence. The midpoint of each age group was considered as the age of diagnosis. Also 5-year survival rates were used to calculate the proportion of incident cases that would be disease-free after 5 years or less with the remaining new cases considered as non-survivors dying of the condition within 5 years.
Supplementary data, Appendix 2 presents the underlying assumptions to estimate DALYs for lung, breast, bone, haematological and non-melanoma skin cancers as these were cancer sites for which some epidemiological information was missing for England and Wales.
All malignant neoplasms that were not assessed individually were grouped as 'Other' cancers. Age-and sex-specific YLD for this residual category were estimated by applying the average YLL/YLD ratio for all the other malignant neoplasms. 24 Site-specific cancers were ranked by DALYs and by crude mortality rates and differences in ranking 
Results

Epidemiological data-cancer registrations and mortality
Cancer registration rates and cancer-specific mortality rates are shown in Table 1 . The highest rate of cancer registrations were for prostate and lung cancers in males, and for breast and lung cancers in females. Non-melanoma skin cancers were common in both males and females. 
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shown in Table 2 . Only 4% of all cancer DALYs among males and 5% among females occurred under the age of 40 years. Also, despite incidence of most cancers increasing in older age, men and women of 65-74 years of age experienced the highest DALYs.
The greatest burden of disease due to cancer was attributable to lung cancer, followed by colorectal, breast and prostate cancers. The high burden from all cancers was mainly due to mortality (86% of the DALYs were due to YLL).
Lung cancer accounted for 27% of all cancer DALYs among males and 20% of all cancer DALYs among females. Among females, 22% of all cancer DALYs were due to breast cancer. Colorectal cancers accounted for 9% of all cancer DALYs among males and 7% of all cancer DALYs among females. Proportional contribution of YLL due to death towards DALYs Table 1 shows the proportion of DALYs due to years of life lost by cancer site and sex. Among males, conditions with the highest YLL components were for liver (98%), pancreatic (97%), brain (95%), oesophageal (95%) and lung (94%) cancers. Among females, the cancers with the highest proportions of YLL were liver (98%), pancreatic (98%), brain (95%), lung (95%) and oesophageal (95%) cancers. Time lost through early deaths due to lung cancer accounted for majority of DALYs as only 5% of DALYs were due to YLD.
Proportional contribution of YLD towards DALYs
Testicular cancer among males and Hodgkin's disease among both sexes had highest proportion of burden due to the disability component (60 and 65%, respectively). YLD accounted for 30% of breast cancer DALYs among cancers in females and 24% of DALYs due to prostate cancer among males. YLD accounted for 15% of the DALYs in colon cancers and 34% for rectal cancers overall for males and females. In this study, among females, 22% of all cancer DALYs were due to breast cancer. YLD of breast cancer accounted for 30% of DALYs, is probably because of the high number of new registrations of breast cancer among younger females. Among males, although prostate cancer had the highest registration, however, lung cancer contributed to the highest death rate. The DALYs per 100 000 for lung cancer (895 DALYs/100 000) was more than double that of prostate cancer (342 DALYs/100 000).
DALYs and event-based metrics
In these calculations, the age-specific burden of disease due to cancer was estimated. Detailed knowledge of the most affected age groups can be useful for conditions with population-based screening as it can identify the target age groups which are most likely to benefit. The proportion of YLL and YLD in different conditions may be useful when identifying interventions to address disease-specific issues. For example, in conditions with high lethality like lung cancer, it may be seen more important to prevent primary occurrence but for a condition that is less lethal, the improvement to quality of life after diagnosis and treatment and prevention of disease progression can be seen important. Burden of disease estimates, particularly unified measures such as DALY can also be used to monitor services and conduct health economic analyses like cost-effectiveness studies. 27 Mortality and morbidity are both important aspects to consider when service planning and commissioning. DALY estimates provide a summary of both perspectives.
What is already known on this topic?
Previous studies of DALYs from major conditions have calculated YLL using local mortality figures, but borrowed regional YLD estimates from GBD 5 or World Bank. 6 A study in two London Boroughs which used this approach, estimated a cancer burden of 2148 DALYs/100 000 population which was comparable to the WHO estimate. 5 In Australia, New Zealand, Spain and Serbia, the top three cancers responsible for the highest burden of disease were lung, colorectal and breast cancers. 28 -31 When comparing burden from cancer in England and Wales to those of other countries, the same cancers led to highest burden.
What this study adds
In this study, DALYs were calculated based on 5-year data on cancer registrations and mortality in order to reduce year-on-year variation. The use of standard life tables will allow findings to be compared with disease burden estimates from other countries as well as other conditions.
The study also provides DALYs for 27 cancer sites for England and Wales by gender and age group. This study provides a comparison between magnitudes of mortality experiences to that of DALYs for individual cancer sites.
Limitations of this study
The standard life tables of WHO has a life expectancy for females of 82.5 and 80 years for males. 24 These figures are higher than the life expectancy of England and Wales and could be interpreted as over-estimating YLLs. However, the process of assigning YLL based on a common (rather than local) life table is deliberate and allows better comparability. In addition, survival data were not available for individuals aged ,15 years, instead survival data for adults aged 15 -39 years were used in the DALY calculations for children. However, this is likely to have minimal impact on the estimates as around 1000 out of 240 000 new registrations were for cancers in people aged 15 or younger. Complexities of DALY calculations include requirements of multiple data sets and assumptions. Estimation of DWs affect final DALY results, both in terms of overall disease burden and cancer ranking. The Victorian BoD Programme of DWs for different disease stages was used as each weight which was likely to be more reflective of the stage-specific disability. Discounting gives more weight to deaths that occur nearer to the present time increasing the proportion of disease burden due to YLD and decrease the burden of disease in children. On the other hand, age weighting most likely inflates cancers that are common in the middle ages with most affected cancers likely to be breast cancer, leukaemia, malignant melanoma, brain cancer and lymphomas. The final outcome is that discounting adds more weight to older ages and age weighting gives less weight to older age groups. 24 Cancer registration is mandatory for the NHS, including trusts. The proportion of registrations that result from 'death certificate only (DCO)' is an indicator for completeness of registrations. Currently, most registries have DCO ,2%, which suggests registration is close to complete. 32 For cases that have been registered solely from death certificate information, the incidence date is unknown and has to be taken as the date of death and the case may well be recorded against the wrong calendar year.
No adjustment could be made for co-morbidity. In addition, during YLL estimation, all deaths that were attributed to cancer were assumed as actual deaths due to cancer. According to ONS, around 0.2% of all deaths registered would have the cause of death changed.
The method of handling 'ill-defined' malignancies used may limit comparability of the results with those of other studies that used a different redistribution methodology.
YLD estimations require several assumptions. The duration of the disease was estimated based on 5-year survival figures where the morbidity measure of the condition ended at 5 years for the survivors, i.e. DW for long-term survivors was zero after 5 years from initial diagnosis. This is likely to underestimate the burden from some malignant neoplasms, with particular reference to cancers with longer duration such as breast or prostate cancer.
Conclusions
DALYs are complex measures that draw upon principles from demography, epidemiology and economics. The methodology to derive DALYs will continue to receive technical criticisms. If a tool is to be useful in public health it needs to be readily available, easy to use and consistent across time and place. No one metric of disease occurrence is optimal for all purposes and the burden of disease analyses can add usefully to information available for service planning. The addition of the disability component changes the relative position of some of the top cancers. Although metrics based on deaths alone capture most effects of cancer on population health levels, important additional perspectives, relevant to the planning of services, can be gained from burden of disease analyses.
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